Filtered By:
Source: Diabetes, Obesity and Metabolism
Condition: Diabetes Mellitus
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
Gender‐specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus
ConclusionsOral insulin sensitizers, particularly thiazolidinedione, are associated with decreased malignancy risk in women with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - December 5, 2013 Category: Endocrinology Authors: G. E. C. Sun, B. J. Wells, K. Yip, R. Zimmerman, D. Raghavan, M. W. Kattan, S. R. Kashyap Tags: ORIGINAL ARTICLE Source Type: research
Gender‐Specific Effects of Oral Hypoglycemic Agents on Cancer Risk in Type 2 Diabetes Mellitus
ConclusionsOral insulin sensitizers, particularly thiazolidinedione, are associated with decreased malignancy risk in women with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - November 6, 2013 Category: Endocrinology Authors: Grace E. Ching Sun, Brian J. Wells, Kathleen Yip, Robert Zimmerman, Derek Raghavan, Michael W. Kattan, Sangeeta R. Kashyap Tags: Original Paper Source Type: research
Observational follow‐up of the PROactive study: a 6‐year update†
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - August 19, 2013 Category: Endocrinology Authors: E. Erdmann, E. Song, R. Spanheimer, A.‐R. van Troostenburg de Bruyn, A. Perez Tags: ORIGINAL ARTICLE Source Type: research
